1. Home
  2. DLXY vs GDTC Comparison

DLXY vs GDTC Comparison

Compare DLXY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DLXY

Delixy Holdings Limited Ordinary Shares

N/A

Current Price

$0.98

Market Cap

15.5M

Sector

N/A

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.05

Market Cap

15.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLXY
GDTC
Founded
2007
2018
Country
Singapore
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.5M
15.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DLXY
GDTC
Price
$0.98
$1.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
42.1K
455.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
$11.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.73
52 Week High
$7.00
$3.68

Technical Indicators

Market Signals
Indicator
DLXY
GDTC
Relative Strength Index (RSI) 51.67 47.58
Support Level $0.85 $0.87
Resistance Level $0.96 $2.25
Average True Range (ATR) 0.08 0.11
MACD 0.01 0.02
Stochastic Oscillator 38.12 45.25

Price Performance

Historical Comparison
DLXY
GDTC

About DLXY Delixy Holdings Limited Ordinary Shares

Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: